Biomedical papers - Ahead of Print

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | 10.5507/bp.2017.001

Amyloid cardiomyopathy

Lucie Karafiatovaa, Tomas Pikab
a Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic
b Department of Hemato-Oncology, University Hospital Olomouc, Czech Republic

Amyloidosis is a heterogeneous group of diseases characterized by the deposition of amyloid. It is caused by extracellular deposition of insoluble fibrils with beta-pleated sheet configuration. The protein misfolding abnormalities result in amyloid fibrils and may manifest as primary, secondary, or familial amyloidosis. Amyloid deposition can occur in multiple organs (eg, heart, liver, kidney, skin, eyes, lungs, nervous system) resulting in a variety of clinical manifestations. Cardiac involvement can occur as part of a systemic disease or as a localized phenomenon. Cardiac involvement in all types of amyloidosis represents a major negative prognostic factor. Early diagnosis, multi-disciplinary cooperation and proper therapy are key aspects of care for patients with amyloid cardiomyopathy. Early diagnosis is crucial, especially in AL amyloidosis, as patients with advanced heart disease are unsuitable candidates for modern, effective hematological treatment including autologous stem cell transplantation. Despite signal development in diagnostics and therapy, the prognosis for patients with advanced cardiac involvement remains poor. This article is an overview of amyloidosis, providing information about the characteristics of cardiac amyloidosis, and present a structured approach to diagnosis, treatment and prognosis of this condition.

Keywords: amyloidosis, amyloid cardiomyopathy, heart diseases, heart failure, restrictive cardiomyopathy

Received: October 16, 2016; Accepted: January 9, 2017; Prepublished online: February 1, 2017


References

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96. Go to original source... Go to PubMed...
  2. Lachman HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol 2006;6:214-20. Go to original source... Go to PubMed...
  3. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;1924-33.
  4. Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcome. Am J Hematol 2006;81:692-5. Go to original source... Go to PubMed...
  5. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 2012;26:137-54. Go to original source... Go to PubMed...
  6. Palecek T, Fikrle M, Nemecek E, Bauerova L, Kuchynka P, Louch WE, Spicka I, Rysava R. Contemporary treatment of amyloid heart disease. Curr Pharm Des 2015;21:491-506. Go to original source... Go to PubMed...
  7. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-10. Go to original source... Go to PubMed...
  8. Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: A practical approach to diagnosis and management. Am J Med 2011;124:1006-15. Go to original source... Go to PubMed...
  9. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Therapeutics 2014;39:225-33. Go to original source... Go to PubMed...
  10. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300. Go to original source... Go to PubMed...
  11. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphan J Rare Dis 2013;8:31. Go to original source... Go to PubMed...
  12. Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528-40. Go to original source... Go to PubMed...
  13. de Asúa DR, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014;6:369-77. Go to original source... Go to PubMed...
  14. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22. Go to original source... Go to PubMed...
  15. Ariyarajah V, Steiner I, Hajkova P, Khadem A, Kvasnicka J, Apiyasawat S, Spodick DH. The association of atrial tachyarrhytmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009;113:132-7. Go to original source... Go to PubMed...
  16. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med 1998;91:141-57. Go to original source... Go to PubMed...
  17. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124-30. Go to original source... Go to PubMed...
  18. Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ, Hawkins PN, Pratt G. Guidelines on the diagnosis and investigation of AL amyloidosis. Brit J Hematol 2015;168:207-18. Go to original source... Go to PubMed...
  19. Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol 2014;89:1133-40. Go to original source... Go to PubMed...
  20. Molle P, Renaut P, Gottlieb D, Goodman H. How to diagnose amyloidosis. Int Med J 2014;44:7-17. Go to original source... Go to PubMed...
  21. Picken MM. Amyloidosis - where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545-51. Go to PubMed...
  22. Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2012;120:3206-13. Go to original source... Go to PubMed...
  23. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL) A consensus opinion from the 10th International Symposium on amyloid and amyloidosis. Am J Hematol 2005;79:319-28. Go to original source... Go to PubMed...
  24. Dispenzieri A, Gertz MA, Kyel RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CGA, Jaffe AS. Serum cardiac troponins nad N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7. Go to original source... Go to PubMed...
  25. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-7. Go to original source... Go to PubMed...
  26. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-95. Go to original source... Go to PubMed...
  27. Kristen AV, Giannittsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, Hardt S, Schnabel PA, Röcken C, Schonland SO, Ho AD, Dengler TJ, Katus HA. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010;116:2455-61. Go to original source... Go to PubMed...
  28. Apridonidze T, Steingart RM, Comenzo RL, Hoffman J, Goldsmith Y, Bella JN, Landau H, Liu JE. Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. Am J Cardiol 2012;110:1180-4. Go to original source... Go to PubMed...
  29. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5. Go to original source... Go to PubMed...
  30. Lehrke S, Steen H, Kristen AV, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187-95. Go to original source... Go to PubMed...
  31. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers. Impact on survival outcomes. J Clin Oncol 2012;30:4541-9. Go to original source... Go to PubMed...
  32. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012;87:465-71. Go to original source... Go to PubMed...
  33. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010;85:757-9. Go to original source... Go to PubMed...
  34. Dubrey S. Amyloid heart disease. Br J Cardiol 2009;16:36-41.
  35. Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol 2013;18:157-62. Go to original source... Go to PubMed...
  36. Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013;18:271-80. Go to original source... Go to PubMed...
  37. Murtagh B, Hammil SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95:535-7. Go to original source... Go to PubMed...
  38. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004;43:410-15. Go to original source... Go to PubMed...
  39. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014;114:1089-93. Go to original source... Go to PubMed...
  40. Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, Garini P, Merlini G. Holter monitoring in AL amyloidosis: prognostic implications. PACE 2001;24:1228-33. Go to original source... Go to PubMed...
  41. Falk RH, Rubinow A, Cohen AS. Cardiac arrhytmias in systemic amyloidosis: correlation with echocardiograhic abnormalities. JACC 1984;3:107-13. Go to original source... Go to PubMed...
  42. Reyners AKL, Hezenberg BPC, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002;23:157-61. Go to original source... Go to PubMed...
  43. Falk RH. Diagnosis and management of the cardiac amyloidosis. Circulation 2005;112:2047-60. Go to original source... Go to PubMed...
  44. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985;6:737-43. Go to original source... Go to PubMed...
  45. Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, Seward JB, Tajik AJ. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;16:1135-41. Go to original source... Go to PubMed...
  46. Fitzgerald BT, Scalia GM, Cain PA, Garcia MJ, Thomas JD. Left atrial size:another differentiator for cardiac amyloidosis. Heart Lung Circ 2011;20:574-8. Go to original source... Go to PubMed...
  47. Navarro JF, Rivera M, Ortuno J. Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol 1992;36:107-8. Go to original source... Go to PubMed...
  48. D'Hooge J, Heimdal A, Jamal F. Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur J Echocardiogr 1; 2000:154-70. Go to original source... Go to PubMed...
  49. Heimdal A, Stoylen A, Torp H, Skjaerpe T. Real-time strain rate imaging of the left ventricle by ultrasound. J Am Soc Echocardiogr 11;1998:1013-9. Go to original source... Go to PubMed...
  50. Bellavia D, Pellikka PA, Dispenzieri A, Scott CG, Al-Zahrani GB, Grogan M, Pitrolo F, Oh JK, Miller FA. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (al) amyloidosis: A 5-year cohort study. Eur Heart J Cardiovasc Imaging 2012;13:680-9. Go to original source... Go to PubMed...
  51. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649-55. Go to original source... Go to PubMed...
  52. Hazenberg BPC, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, Hawkins PN, Jager PL. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:e15-24. Go to original source... Go to PubMed...
  53. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti F, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. J Am Coll Cardiol Img 2011;4:659-70. Go to original source... Go to PubMed...
  54. Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti, P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. Go to original source... Go to PubMed...
  55. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Hrding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93. Go to original source... Go to PubMed...
  56. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, Lovato L, Branzi A, Fattori R. Non-invasicve evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92:343-9. Go to original source... Go to PubMed...
  57. Hosch W, Kristen AV, Libicher M, Dengler TJ, Aulmann S, Heye T, Schnabel PA, Schirmacher P, Katus HA, Kauczor HU, Longerich T. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid 2008;15:196-204. Go to original source... Go to PubMed...
  58. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis. J Am Coll Cardiol 2008;51:1022-30. Go to original source... Go to PubMed...
  59. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img 2010;3:155-64. Go to original source... Go to PubMed...
  60. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014; 7(2):157-65. Go to original source... Go to PubMed...
  61. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6(1):34-9. Go to original source... Go to PubMed...
  62. Duston MA, Skinner M, Meenan RF. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 1989;32:82-5. Go to original source... Go to PubMed...
  63. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN. Sequential heart and autologous transplantation for systemic AL amyloidosis. Blood 2006;107:1227-9. Go to original source... Go to PubMed...
  64. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3. Go to original source... Go to PubMed...
  65. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3. Go to original source... Go to PubMed...
  66. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in series of 421 patients. Blood 2011;118:4346-52. Go to original source... Go to PubMed...
  67. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82. Go to original source... Go to PubMed...
  68. Gertz MA, Lacy MQ, Dispenzieri D, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef INM, Porrata LF, Leung N, Hogan WJ, Buadi FK. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 2010;51:2181-7. Go to original source... Go to PubMed...
  69. Jimenez-Zepeda VH, Franke N, Reece DE, Trudel S, Chen C, Delgado DH, Winter A, Mikhael JR, Tiedemann R, Kukreti V. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution. Brit J Hematol 2014;164:722-8. Go to original source... Go to PubMed...
  70. Perfetti G, Obici V, Caccialanza L, Semino R, Adami A, Cavallero F, Rustichelli G, Virga R, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8. Go to original source... Go to PubMed...
  71. Dietrich S, Schönland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Hoand AD, Hegenbart U. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with nexly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116:522-8. Go to original source... Go to PubMed...
  72. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-51. Go to original source... Go to PubMed...
  73. Palladini G, Russo P, Lavaelli F, Nuvolone M, Albertini R, Bosoni T, Perfetti V, Obici L, Perlini S, Moratti R, Merlini G. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009;88:347-50. Go to original source... Go to PubMed...
  74. Maurere MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015;8:519-26. Go to original source... Go to PubMed...
  75. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19:34-6. Go to original source... Go to PubMed...
  76. Sack F-U, Kristen AV, Goldsmith H, Schnabel PA, Dengler T, Koch A, Karck M. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patientswith AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33:257-62. Go to original source... Go to PubMed...
  77. Obici L, Cortese A, Lozza A, Luchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19:34-6. Go to original source... Go to PubMed...
  78. Fikrle M, Palecek T, Kuchynka P, Nemecek E, Bauerova L, Straub J, Rysava R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa 2013;55:e60-e75. Go to original source...